Benzinga's Top Downgrades - Bristol-Myers Squibb (NYSE:BMY)

Berenberg downgraded Bristol-Myers Squibb Co BMY from Buy to Hold. The price target for Bristol-Myers Squibb has been lowered from $80 to $70. Bristol-Myers Squibb shares rose 0.36 percent to $60.80 in pre-market trading.
Analysts at Ladenburg Thalmann downgraded Zosano Pharma Corp ZSAN from Buy to Neutral. Zosano Pharma shares fell 2.14 percent to close at $1.37 on Wednesday.
Scotia Howard Weil downgraded EQT Corporation EQT from Sector Outperform to Sector Perform. EQT shares dropped 0.84 percent to close at $68.25 on Wednesday.
Analysts at Keefe Bruyette & Woods downgraded PHH Corporation PHH from Outperform to Market Perform. PHH shares declined 0.67 percent to $14.82 in pre-market trading.
Barrington Research downgraded EPIQ Systems, Inc. EPIQ from Market Perform to Underperform. Epiq Systems shares fell 0.18 percent to $16.31 in pre-market trading.
Nomura downgraded Lam Research Corporation LRCX from Buy to Neutral. Lam Research shares declined 4.48 percent to close at $89.11 on Wednesday.
Analysts at Morgan Stanley downgraded Lumentum Holdings Inc LITE from Equal-weight to Underweight. The price target for Lumentum Holdings has been raised from $20 to $27. Lumentum Holdings shares rose 0.29 percent to close at $55.72 on Wednesday.
Analysts at Evercore ISI Group downgraded Scripps Networks Interactive, Inc. SNI from Buy to Hold. Scripps Networks shares gained 1.04 percent to close at $62.11 on Wednesday.
Ladenburg Thalmann downgraded Zosano Pharma Corp ZSAN from Buy to Neutral. Zosano Pharma shares dropped 2.14 percent to close at $1.37 on Wednesday.

Market News and Data brought to you by Benzinga APIs